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Sequential combination of Ugi-MCR and click chemistry has been employed for the synthesis of triazole
linked cyclic glycopeptidomimetics. The protocol employs Poc-amino alkyl isonitriles, sugar-1-amines,
azido acids, and simple aldehydes as precursors. The dual nature of the propargyloxycarbonyl (Poc)
group was explored for amine protection as well as cycloaddition with an azide. All the cyclic
glycopeptidomimetics are isolated and characterized.
 2012 Elsevier Ltd. All rights reserved.1Afﬂuence of cyclic glycopeptides in natural sources and the
knowledge about their biological and structural signiﬁcance
emphasize the importance of the development of synthetic meth-
odologies for such molecules and related analogs. From the bio-
chemist’s perspective, glycopeptide cyclization is an interesting
aspect of study that may lead to valuable architectural repertoire
possessing structurally and pharmacologically useful properties.2
Cyclic glycopeptides do not possess ionizable N- and C-terminals
rendering themwith improved membrane permeability and stabil-
ity to in vivo enzymatic degradation.3 However, cyclization is, in
general, yield-limiting and synthetically a difﬁcult step. This
evokes to suitably design the sites for gluing the head to tail afford-
ing a ring structure in an efﬁcient manner through the establish-
ment of a native or non-native linkage.4 On the other hand,
substantial focus has been paved toward development of new pro-
tocols for the construction of glycopeptidomimetics5 and peptido-
mimetcis.6 In the former, the carbohydrate is linked to peptide
backbone through a non-native linkage and in the latter class of
molecules, one or more amide bonds in the backbone are replaced
by artiﬁcial tethers.
Multi-component reactions such as Ugi-MCR7 and Passerini-
3CR8 are being utilized for accessing complex molecules from sim-
ple substrates.9 Isonitrile based MCRs, especially those involving
isocyano esters have emerged as tools of choice to access peptide-
like constructs.10 It is useful to tag MCRs with another reaction(s)ll rights reserved.
obile: +91 09986312937.
gmail.com, sureshbabuvomin a sequential manner so as to modify the Ugi-product to obtain
desired products.11 Till recently, isocyano esters, prepared by N-
modiﬁcation of amino acid esters were the isonitrile components
generally used in the MCRs. Sureshbabu and co-workers described
another class of amino acid derived isonitriles by modifying the C-
terminus of N-protected amino acids and the resulted N-protected
amino alkyl isonitriles have been employed as key substrates in a
couple of MCRs to obtain a few peptidomimetics.12 The Cu-cata-
lyzed azide–alkyne cycloaddition (‘click’ chemistry)13 is a robust
chemical transformation in bridging two components. This reaction
has accelerated the research in drug discovery due to the efﬁcient
and non-sensitive reaction conditions, thus ideal for the synthesis
of a library of compounds. Triazole has been used as a surrogate
to the native bond in the synthesis of cyclic peptidomimetic and
glycopeptidomimetic scaffolds14 involving multistep protocol. Our
interest in the development of a useful strategy for accessing cyclic
neoglyco-peptidomimetics led us to explore a sequential combina-
tion of Ugi-MCR and azide–alkyne cycloaddition as a tool to synthe-
size the title compounds.
The present study involves the design of suitable starting com-
ponents for MCR that would yield a linear molecule which can be
cyclized through click reaction. A combination of an isonitrile,
amine, aldehyde, and a carboxy compound would lead to a linear
peptidic derivative wherein the isonitrile and carboxy acid compo-
nents ﬂank at either terminus. This directed us to deposit the
alkyne and azide groups required to operate post-MCR step, in
the isonitrile and carboxy substrates before initiating the MCR. In
this context, it is to note that both azide and alkyne groups are
compatible to Ugi reaction conditions. The azido acid was an
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amino acid precursor in peptide bond formation. Another key as-
pect is to obtain a linear peptidic unit possessing both isonitrile
and alkyne groups as terminals. The dual utility of propargyloxy-
carbonyl (Poc) group can be explored for amino protection as well
as a reactant for Huisgen’s cycloaddition reaction.15 Thus, Poc-pro-
tected amino alkyl isonitriles are chosen as suitable substrates in
this protocol. The sugar component was selected as an amino com-
ponent which can be prepared easily. The aldehydes were selected
from the commercially available sources.O
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Table 1
List of Ugi products 5a–5h and cyclic glycopeptidomimetics 6a–6h
Entry Poc-Xaa-w[CH2NC] (1) Aldehyde (2) Azido acid (3)
1 Phe
OHC
Ala
2 Leu
CHO
Gly
3 Gly
CHO
Leu
4 Val
O
CHO
Leu
5 Leu
CHO
Gly
6 Ala
OHC
Phe
7 Isoleucine HCHO Val
8 Phe
O
CHO
AlaThe preparation of the substrates was straightforward and sim-
ple. Brieﬂy, azido acids were prepared by a reaction of amino acids
with imidazole-1-sulfonyl azide as reported by Goddard-Borger.16
For the preparation of 2,3,4,6-tetra-O-acetyl glucosyl-1-amine,
glucose was reacted with acetyl chloride and the resulting
1,2,3,4,6-penta-O-acetyl-a,b-D-glucopyranose was reacted with
HBr in AcOH to obtain 2,3,4,6-tetra-O-acetyl glycopyranosyl-1-bro-
mide. Replacement of bromide with azide followed by catalytic
hydrogenation of the azido group afforded 2,3,4,6-tetra O-acetyl
glucopyranosyl-1-amine.17 Poc-amino acids were prepared byNH
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and co-workers18 The carboxy terminus was modiﬁed into methy-
lene isonitrile through a series of operations as described previ-
ously by us.19
The Ugi MCR was initiated by mixing equimolar quantities of
the four reactants in MeOH. In a typical reaction, Poc-Val-
w[CH2NC] 1d, azido-Leucine 3d were added to a stirred solution
of furfural 2d and 2,3,4,6-tetra O-acetyl glucopyranosyl-1-amine
4d in MeOH under nitrogen (Scheme 1). The course of the reaction
was monitored through TLC. After 24 h, the crude reaction mixture
was column chromatographed to obtain the desired linear peptidic
product 5d as solid in 73% yield. As expected, the product was a
mixture of two diastereomers. The chiral HPLC analysis revealed
that the two compounds were present in the ratio-95:5; however,
the isomers were not separated any further. The same protocol was
utilized to prepare a series of examples of Ugi adducts 5a–5h
(Table 1).20 In the ultimate step, the head to tail cyclization of thus
obtained linear molecule was undertaken.
During the cyclization reactions, dimerization and oligomeriza-
tion are a concern.21 This aspect is usually circumvented by taking
millimolar concentration of the reaction mixture. However, the
problem will not be so serious if the ring size is large so as to keep
the strain at minimum.22 In the present case, when the linear mol-
ecule 5d was subjected to Cu catalyzed azide–alkyne cycloaddi-
tion, the designed triazole linked cyclic neoglycopeptide was
formed as a major component along with only a small amount of
dimer and meager quantities of other unidentiﬁed byproducts. It
can be reasoned that the target molecule is a 15-membered ring
and thus the ring strain is less due to which mono-cyclization is
the major reaction.
In the initial experiment for the cyclization of 5d, the catalytic
system comprising CuSO45H2O/sodium ascorbate in tBuOH/water
was used. It led to 6d in 62% yield in about 10 h at rt. In order to
improve the yield as well as to reduce the duration of reaction,
other catalysts CuI/DIPEA in acetonitrile and CuBr/1,8-Diazabicy-
clo[5.4.0] undec-7-ene (DBU) in toluene were explored. Both sys-
tems yielded only 40% and 46% of the cyclized product 6d. In
light of these results, the CuSO4/sodium ascorbate was ﬁnally cho-
sen and thus was utilized in the synthesis of 6a–6h. In a typical
reaction,23 CuSO4 (0.02 equiv, 0.64 mg), sodium ascorbate
(0.3 equiv, 7.6 mg) were added to the solution of linear peptidic
component 5d (100 mg 0.128 mmol) in tBuOH/water (3:1;
120:40 mL). The resulting solution was allowed to stir for 10 h at
rt. The reaction was monitored by RP-HPLC. A simple work-up
afforded the target compound along with small amounts of dimer
product. The desired cyclic glycopeptidomimetic 6d was then iso-
lated by column chromatography using n-hexane/EtOAc (40:60) in
62% yield (Table 1). The reaction worked well with other linear
molecules as well. All the products 6a–6h were characterized by
mass and 1H NMR spectroscopy.
In summary, an effective protocol has been designed to access
cyclic glycopeptidomimetics by employing Ugi MCR and click reac-
tions in a sequential manner. Poc-amino alkyl isonitrile is used for
the ﬁrst time in MCR reactions and the alkyne moiety of Poc group
is made to participate in the intramolecular cycloaddition with an
azide situated at the other terminus. The resulting cyclic neoglyco-
peptidomimetic was isolated in moderate yield and characterized.
Click reaction is very efﬁcient in bringing out the cyclization with-
out considerable byproducts.
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